TY - JOUR
T1 - Characterization and Management of Arrhythmic Events in Young Patients With Brugada Syndrome
AU - Michowitz, Yoav
AU - Milman, Anat
AU - Andorin, Antoine
AU - Sarquella-Brugada, Georgia
AU - Gonzalez Corcia, M Cecilia
AU - Gourraud, Jean-Baptiste
AU - Conte, Giulio
AU - Sacher, Frederic
AU - Juang, Jimmy J M
AU - Kim, Sung-Hwan
AU - Leshem, Eran
AU - Mabo, Philippe
AU - Postema, Pieter G
AU - Hochstadt, Aviram
AU - Wijeyeratne, Yanushi D
AU - Denjoy, Isabelle
AU - Giustetto, Carla
AU - Mizusawa, Yuka
AU - Huang, Zhengrong
AU - Jespersen, Camilla H
AU - Maeda, Shingo
AU - Takahashi, Yoshihide
AU - Kamakura, Tsukasa
AU - Aiba, Takeshi
AU - Arbelo, Elena
AU - Mazzanti, Andrea
AU - Allocca, Giuseppe
AU - Brugada, Ramon
AU - Casado-Arroyo, Ruben
AU - Champagne, Jean
AU - Priori, Silvia G
AU - Veltmann, Christian
AU - Delise, Pietro
AU - Corrado, Domenico
AU - Brugada, Josep
AU - Kusano, Kengo F
AU - Hirao, Kenzo
AU - Calo, Leonardo
AU - Takagi, Masahiko
AU - Tfelt-Hansen, Jacob
AU - Yan, Gan-Xin
AU - Gaita, Fiorenzo
AU - Leenhardt, Antoine
AU - Behr, Elijah R
AU - Wilde, Arthur A M
AU - Nam, Gi-Byoung
AU - Brugada, Pedro
AU - Probst, Vincent
AU - Belhassen, Bernard
N1 - Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
PY - 2019/4/16
Y1 - 2019/4/16
N2 - BACKGROUND: Information on young patients with Brugada syndrome (BrS) and arrhythmic events (AEs) is limited.OBJECTIVES: The purpose of this study was to describe their characteristics and management as well as risk factors for AE recurrence.METHODS: A total of 57 patients (age ≤20 years), all with BrS and AEs, were divided into pediatric (age ≤12 years; n = 26) and adolescents (age 13 to 20 years; n = 31).RESULTS: Patients' median age at time of first AE was 14 years, with a majority of males (74%), Caucasians (70%), and probands (79%) who presented as aborted cardiac arrest (84%). A significant proportion of patients (28%) exhibited fever-related AE. Family history of sudden cardiac death (SCD), prior syncope, spontaneous type 1 Brugada electrocardiogram (ECG), inducible ventricular fibrillation at electrophysiological study, and SCN5A mutations were present in 26%, 49%, 65%, 28%, and 58% of patients, respectively. The pediatric group differed from the adolescents, with a greater proportion of females, Caucasians, fever-related AEs, and spontaneous type-1 ECG. During follow-up, 68% of pediatric and 64% of adolescents had recurrent AE, with median time of 9.9 and 27.0 months, respectively. Approximately one-third of recurrent AEs occurred on quinidine therapy, and among the pediatric group, 60% of recurrent AEs were fever-related. Risk factors for recurrent AE included sinus node dysfunction, atrial arrhythmias, intraventricular conduction delay, or large S-wave on ECG lead I in the pediatric group and the presence of SCN5A mutation among adolescents.CONCLUSIONS: Young BrS patients with AE represent a very arrhythmogenic group. Current management after first arrhythmia episode is associated with high recurrence rate. Alternative therapies, besides defibrillator implantation, should be considered.
AB - BACKGROUND: Information on young patients with Brugada syndrome (BrS) and arrhythmic events (AEs) is limited.OBJECTIVES: The purpose of this study was to describe their characteristics and management as well as risk factors for AE recurrence.METHODS: A total of 57 patients (age ≤20 years), all with BrS and AEs, were divided into pediatric (age ≤12 years; n = 26) and adolescents (age 13 to 20 years; n = 31).RESULTS: Patients' median age at time of first AE was 14 years, with a majority of males (74%), Caucasians (70%), and probands (79%) who presented as aborted cardiac arrest (84%). A significant proportion of patients (28%) exhibited fever-related AE. Family history of sudden cardiac death (SCD), prior syncope, spontaneous type 1 Brugada electrocardiogram (ECG), inducible ventricular fibrillation at electrophysiological study, and SCN5A mutations were present in 26%, 49%, 65%, 28%, and 58% of patients, respectively. The pediatric group differed from the adolescents, with a greater proportion of females, Caucasians, fever-related AEs, and spontaneous type-1 ECG. During follow-up, 68% of pediatric and 64% of adolescents had recurrent AE, with median time of 9.9 and 27.0 months, respectively. Approximately one-third of recurrent AEs occurred on quinidine therapy, and among the pediatric group, 60% of recurrent AEs were fever-related. Risk factors for recurrent AE included sinus node dysfunction, atrial arrhythmias, intraventricular conduction delay, or large S-wave on ECG lead I in the pediatric group and the presence of SCN5A mutation among adolescents.CONCLUSIONS: Young BrS patients with AE represent a very arrhythmogenic group. Current management after first arrhythmia episode is associated with high recurrence rate. Alternative therapies, besides defibrillator implantation, should be considered.
U2 - 10.1016/j.jacc.2019.01.048
DO - 10.1016/j.jacc.2019.01.048
M3 - Journal article
C2 - 30975291
SN - 0735-1097
VL - 73
SP - 1756
EP - 1765
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 14
ER -